Lovedeep Singh Dhingra

Lovedeep Singh Dhingra

Auto-generated profile, based on publicly available information

Lovedeep Singh Dhingra

Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 August 2023 in Circulation
Verified
Journal Article
Closed access
VSVeer Sangha
Veer Sangha
ANArash A. Nargesi
Arash A. Nargesi
LDLovedeep S. Dhingra
Lovedeep S. Dhingra
AKAkshay Khunte
Akshay Khunte
BMBobak Jack Mortazavi
Bobak Jack Mortazavi
RKRohan Khera
Rohan Khera
BACKGROUND: Left ventricular (LV) systolic dysfunction is associated with a >8-fold increased risk of heart failure and a 2-fold risk of premature death. The use of ECG signals in screening for LV systolic dysfunction is limited by their availability to clinicians. We developed a novel deep learning–based approach that can use ECG images for the screening of LV systolic dysfunction. METHODS: Using 12-lead ECGs plotted in multiple different formats, and corresponding echocardiographic data recorded within 15 days from the Yale New Haven Hospital between 2015 and 2021, we developed a convolutional neural network algorithm to detect an LV ejection fraction 27-fold higher odds of LV systolic dysfunction on transthoracic echocardiogram (odds ratio, 27.5 [95% CI, 22.3–33.9] in the held-out set). Class-discriminative patterns localized to the anterior and anteroseptal leads (V 2 and V 3 ), corresponding to the left ventricle regardless of the ECG layout. A positive ECG screen in individuals with an LV ejection fraction ≥40% at the time of initial assessment was associated with a 3.9-fold increased risk of developing incident LV systolic dysfunction in the future (hazard ratio, 3.9 [95% CI, 3.3–4.7]; median follow-up, 3.2 years). CONCLUSIONS: We developed and externally validated a deep learning model that identifies LV systolic dysfunction from ECG images. This approach represents an automated and accessible screening strategy for LV systolic dysfunction, particularly in low-resource settings.

11 July 2023 in npj Digital Medicine
Verified
Journal Article
Open access
PDF file
AKAkshay Khunte
Akshay Khunte
VSVeer Sangha
Veer Sangha
EOEvangelos K. Oikonomou
Evangelos K. Oikonomou
LDLovedeep S. Dhingra
Lovedeep S. Dhingra
AAArya Aminorroaya
Arya Aminorroaya
RKRohan Khera
Rohan Khera
Artificial intelligence (AI) can detect left ventricular systolic dysfunction (LVSD) from electrocardiograms (ECGs). Wearable devices could allow for broad AI-based screening but frequently obtain noisy ECGs. We report a novel strategy that automates the detection of hidden cardiovascular diseases, such as LVSD, adapted for noisy single-lead ECGs obtained on wearable and portable devices. We use 385,601 ECGs for development of a standard and noise-adapted model. For the noise-adapted model, ECGs are augmented during training with random gaussian noise within four distinct frequency ranges, each emulating real-world noise sources. Both models perform comparably on standard ECGs with an AUROC of 0.90. The noise-adapted model performs significantly better on the same test set augmented with four distinct real-world noise recordings at multiple signal-to-noise ratios (SNRs), including noise isolated from a portable device ECG. The standard and noise-adapted models have an AUROC of 0.72 and 0.87, respectively, when evaluated on ECGs augmented with portable ECG device noise at an SNR of 0.5. This approach represents a novel strategy for the development of wearable-adapted tools from clinical ECG repositories.

13 January 2025 in European Heart Journal
Verified
Journal Article
Closed access
LDLovedeep S Dhingra
Lovedeep S Dhingra
AAArya Aminorroaya
Arya Aminorroaya
VSVeer Sangha
Veer Sangha
APAline F Pedroso
Aline F Pedroso
FAFolkert W Asselbergs
Folkert W Asselbergs
RKRohan Khera
Rohan Khera
Background and Aims: Current heart failure (HF) risk stratification strategies require comprehensive clinical evaluation. In this study, artificial intelligence (AI) applied to electrocardiogram (ECG) images was examined as a strategy to predict HF risk. Methods: Across multinational cohorts in the Yale New Haven Health System (YNHHS), UK Biobank (UKB), and Brazilian Longitudinal Study of Adult Health (ELSA-Brasil), individuals without baseline HF were followed for the first HF hospitalization. An AI-ECG model that defines cross-sectional left ventricular systolic dysfunction from 12-lead ECG images was used, and its association with incident HF was evaluated. Discrimination was assessed using Harrell’s C-statistic. Pooled cohort equations to prevent HF (PCP-HF) were used as a comparator. Results: Among 231 285 YNHHS patients, 4472 had primary HF hospitalizations over 4.5 years (inter-quartile range 2.5–6.6). In UKB and ELSA-Brasil, among 42 141 and 13 454 people, 46 and 31 developed HF over 3.1 (2.1–4.5) and 4.2 (3.7–4.5) years. A positive AI-ECG screen portended a 4- to 24-fold higher risk of new-onset HF [age-, sex-adjusted hazard ratio: YNHHS, 3.88 (95% confidence interval 3.63–4.14); UKB, 12.85 (6.87–24.02); ELSA-Brasil, 23.50 (11.09–49.81)]. The association was consistent after accounting for comorbidities and the competing risk of death. Higher probabilities were associated with progressively higher HF risk. Model discrimination was 0.718 in YNHHS, 0.769 in UKB, and 0.810 in ELSA-Brasil. In YNHHS and ELSA-Brasil, incorporating AI-ECG with PCP-HF yielded a significant improvement in discrimination over PCP-HF alone. Conclusions: An AI model applied to a single ECG image defined the risk of future HF, representing a digital biomarker for stratifying HF risk.

24 March 2025 in JACC
Verified
Journal Article
Closed access
LDLovedeep S. Dhingra
Lovedeep S. Dhingra
AAArya Aminorroaya
Arya Aminorroaya
VSVeer Sangha
Veer Sangha
APAline F. Pedroso
Aline F. Pedroso
SSSumukh Vasisht Shankar
Sumukh Vasisht Shankar
RKRohan Khera
Rohan Khera

1 January 2025 in Circulation: Cardiovascular Quality and Outcomes
Verified
Journal Article
Closed access
EOEvangelos K. Oikonomou
Evangelos K. Oikonomou
VSVeer Sangha
Veer Sangha
LDLovedeep S. Dhingra
Lovedeep S. Dhingra
AAArya Aminorroaya
Arya Aminorroaya
ACAndreas Coppi
Andreas Coppi
RKRohan Khera
Rohan Khera
BACKGROUND: Risk stratification strategies for cancer therapeutics–related cardiac dysfunction (CTRCD) rely on serial monitoring by specialized imaging, limiting their scalability. We aimed to examine an application of artificial intelligence (AI) to ECG images as a surrogate for imaging risk biomarkers and its association with early CTRCD. METHODS: Across a US-based health system (2013–2023), we identified 1550 patients (aged, 60 [interquartile range, 51–69] years, 1223 [78.9%] women) without cardiomyopathy who received anthracyclines or trastuzumab for breast cancer or non-Hodgkin lymphoma and had ECG performed ≤12 months before treatment. We deployed a validated AI model of left ventricular systolic dysfunction to baseline ECG images and defined low-, intermediate-, and high-risk groups based on AI-ECG left ventricular systolic dysfunction probabilities of <0.01, 0.01 to 0.1, and ≥0.1 (positive screen), respectively. We explored the association with early CTRCD (new cardiomyopathy, heart failure, or left ventricular ejection fraction <50%), or left ventricular ejection fraction <40%, up to 12 months after treatment. In a mechanistic analysis, we assessed the association between global longitudinal strain and AI-ECG left ventricular systolic dysfunction probabilities in studies performed within 15 days of each other. RESULTS: Among 1550 patients without known cardiomyopathy (median follow-up, 14.1 [interquartile range, 13.4–17.1] months), 83 (5.4%), 562 (36.3%), and 905 (58.4%) were classified as high, intermediate, and low risk, respectively, by baseline AI-ECG. A high-risk versus low-risk AI-ECG screen (≥0.1 versus <0.01) was associated with a 3.4-fold and 13.5-fold higher incidence of CTRCD (adjusted hazard ratio, 3.35 [95% CI, 2.25–4.99]) and left ventricular ejection fraction <40% (adjusted hazard ratio, 13.52 [95% CI, 5.06–36.10]), respectively. Post hoc analyses supported longitudinal increases in AI-ECG probabilities within 6 to 12 months of a CTRCD event. Among 1428 temporally linked echocardiograms and ECGs, AI-ECG left ventricular systolic dysfunction probabilities were associated with worse global longitudinal strain (global longitudinal strain, −19% [interquartile range, −21% to −17%] for probabilities <0.1, to −15% [interquartile range, −15% to −9%] for ≥0.5 [ P <0.001]). CONCLUSIONS: AI applied to baseline ECG images can stratify the risk of early CTRCD associated with anthracycline or trastuzumab exposure in the setting of breast cancer and non-Hodgkin lymphoma therapy.

1 January 2022 in Hypertension
Verified
Journal Article
Open access
PDF file
YLYuan Lu
Yuan Lu
YLYuntian Liu
Yuntian Liu
LDLovedeep Singh Dhingra
Lovedeep Singh Dhingra
DMDaisy Massey
Daisy Massey
CCCésar Caraballo
César Caraballo
HKHarlan M. Krumholz
Harlan M. Krumholz
Poor hypertension awareness and underuse of guideline-recommended medications are critical factors contributing to poor hypertension control. Using data from 8095 hypertensive people aged ≥18 years from the National Health and Nutrition Examination Survey (2011–2018), we examined recent trends in racial and ethnic differences in awareness and antihypertensive medication use, and their association with racial and ethnic differences in hypertension control. Between 2011 and 2018, age-adjusted hypertension awareness declined for Black, Hispanic, and White individuals, but the 3 outcomes increased or did not change for Asian individuals. Compared with White individuals, Black individuals had a similar awareness (odds ratio, 1.20 [0.96–1.45]) and overall treatment rates (1.04 [0.84–1.25]), and received more intensive antihypertensive medication if treated (1.41 [1.27–1.56]), but had a lower control rate (0.72 [0.61–0.83]). Asian and Hispanic individuals had significantly lower awareness rates (0.69 [0.52–0.85] and 0.74 [0.59–0.89]), overall treatment rates (0.72 [0.57–0.88] and 0.69 [0.55–0.82]), received less intensive medication if treated (0.60 [0.50–0.72] and 0.86 [0.75–0.96]), and had lower control rates (0.66 [0.54–0.79] and 0.69 [0.57–0.81]). The racial and ethnic differences in awareness, treatment, and control persisted over the study period and were consistent across age, sex, and income strata. Lower awareness and treatment were significantly associated with lower control in Asian and Hispanic individuals ( P <0.01 for all) but not in Black individuals. These findings highlight the need for interventions to improve awareness and treatment among Asian and Hispanic individuals, and more investigation into the downstream factors that may contribute to the poor hypertension control among Black individuals.